Company Overview
Cabaletta Bio, Inc. operates as a clinical-stage biotechnology entity dedicated to the discovery and development of engineered T cell therapies specifically designed for patients suffering from autoimmune diseases. The company functions within the broader healthcare sector and the specialized biotechnology industry, a landscape defined by high capital requirements, rigorous regulatory pathways, and a focus on innovative cell-based treatments that aim to address unmet medical needs. At its current scale, the company maintains a market capitalization of $267.62M and employs a workforce of 154 individuals to support its research and development initiatives. The combination of a market cap under $300 million and a lack of reported annual revenue indicates that Cabaletta Bio is in a pre-commercialization phase where value is derived primarily from intellectual property potential and pipeline progression rather than current sales performance.
Financial Health
The financial profile of Cabaletta Bio, Inc. is characterized by significant negative earnings, with a net income of $-167,856,000 and an EBITDA of $-170,595,008, while reported revenue remains N/A. The substantial gap between the zero revenue figure and the deep net loss reveals a cost structure dominated by heavy research and development expenditures and operational burn typical of clinical-stage ventures that have not yet achieved commercial product sales. The company generates a free cash flow of $-81,283,128, a metric that highlights its ongoing consumption of cash reserves to fund operations and clinical trials, thereby limiting immediate financial flexibility for external expansion or shareholder returns. All three margin metrics reflect this pre-revenue status, with gross margin, operating margin, and profit margin all recorded at 0.0%, indicating that no revenue has been generated to support operating costs or generate profit. Regarding liquidity and leverage, the company holds $133.60M in cash against $27.10M in debt, supported by a current ratio of 2.77 which suggests a robust ability to meet short-term obligations with existing liquid assets. Despite the strong cash position relative to debt, the return on equity stands at -127.0% and the return on assets is -61.5%, metrics that reveal management is currently destroying shareholder value through high operational costs rather than generating returns, a necessary condition for development-stage companies but one that must be reversed upon commercialization.
Valuation Assessment
Valuation metrics for Cabaletta Bio, Inc. present a complex picture due to the absence of earnings, with a trailing twelve-month P/E ratio listed as N/A and a forward P/E of -1.78. The negative forward P/E ratio implies that analysts or data sources are projecting continued losses in the near term, making traditional earnings-based valuation methods inapplicable and suggesting the market prices the stock based on future pipeline potential rather than current profitability. The price-to-book ratio is recorded at 2.49, indicating that the market values the company at a significant premium over its book value, likely reflecting the high value placed on its intangible assets such as patents and clinical trial data. Alternative valuation measures include a price-to-sales ratio of N/A and an EV/EBITDA of -1.19, both of which suggest that the company cannot be valued using standard multiples due to its lack of sales and negative earnings before interest, taxes, depreciation, and amortization. Price volatility is evident in the 52-week range, where the stock has traded between a low of $0.99 and a high of $3.78, meaning the current valuation sits at a level that fluctuates significantly based on clinical data releases and market sentiment. The stock exhibits a beta of 3.28, which indicates that its price is highly volatile and expected to move with much greater intensity than the broader market, posing higher risk for investors compared to large-cap securities.
Growth & Income
Growth metrics for Cabaletta Bio, Inc. show revenue growth year-over-year as N/A and earnings growth year-over-year as N/A, reflecting the reality that the company has not yet generated sales to measure growth rates or compare earnings trajectory against revenue. Because the company is not a dividend payer, the dividend yield is N/A and the payout ratio is 0.0%, meaning the firm retains all available resources to reinvest into its drug development programs rather than distributing income to shareholders. The absence of a dividend policy is consistent with the company's life cycle stage, where earnings are negative and cash is prioritized for sustaining operations and advancing clinical trials rather than paying out returns. Consequently, the overall growth and income profile of Cabaletta Bio is defined entirely by the potential for future commercialization rather than current income generation or historical growth rates, creating a high-risk, high-reward dynamic where value creation depends on successfully transitioning from a clinical-stage asset to a revenue-generating product.